GuideHaematology

FLIPI24: early progression risk in follicular lymphoma

Reading sheet on the FLIPI24 model, which estimates at diagnosis the risk of an event within 24 months in follicular lymphoma treated with immunochemotherapy.

Updated 3 November 2026

When to use it

Newly diagnosed follicular lymphoma requiring treatment, to identify at baseline patients at risk of early progression (POD24) and, above all, to select or stratify patients in clinical trials.

What it is and for whom

Model developed from individual data of 4,485 patients in 10 observational cohorts treated with first-line immunochemotherapy, and externally validated in the LEO cohort and three phase III trials (over 3,700 patients). It predicts the 24-month event rate (progression, retreatment or death) from treatment start.

Keep reading in the app

  • Variables
  • Published interpretation
  • Limitations

Practical tip

It only uses age and four blood tests (haemoglobin, LDH, β2-microglobulin and WBC): it needs neither nodal area count nor stage.

2 more practical tips in the app.

Reference

A support tool for healthcare professionals: it guides and does not replace clinical judgement.

Back to top